Baseline characteristics of the AS-etanercept cohort (n = 49). Values are mean (SD) or median (interquartile range) unless otherwise specified.
| Characteristics | Values |
|---|---|
| Demographic variables | |
| Men, n (%) | 40 (81.6) |
| Age, yrs | 41.8 (9.2) |
| White, n (%) | 38 (77.6) |
| Disease-related variables | |
| Disease duration, yrs | 12.2 (9.1) |
| Symptom duration, yrs | 15.8 (9.9–23.4) |
| Followup duration, yrs | 2.3 (0.7) |
| HLA-B27 positivity, n (%) | 43 (87.8) |
| ESR, < 20 mm/h | 20.0 (6.0–39.0) |
| CRP, < 10 mg/l | 14.0 (3.0–39.0) |
| BASDAI, 0–10 | 5.7 (1.6) |
| BASFI, 0–10 | 5.7 (2.1) |
| BASMI, 0–10 | 4.4 (2.3) |
| History of uveitis, n (%) | 17 (34.7) |
| History of psoriasis, n (%) | 6 (12.2) |
| History of IBD, n (%) | 3 (6.1) |
| History of peripheral arthritis, n (%) | 16 (32.7) |
| Radiographic damage | |
| Total mSASSS, 0–72 | 10.0 (3.8–35.5) |
| Total mSASSS + ThSpine, 0–90 | 12.1 (6.8–42.7) |
| BMD-related variables | |
| BMI, kg/m2 | 26.3 (3.4) |
| Menopausal status, n (%) | 2 (4.1) |
| 1 or more prevalent VFx, n (%) | 6 (12.2) |
| Smoking, current, n (%) | 24 (49.0) |
| BMD variables | |
| BMD hip | 0.903 (0.152) |
| BMD L2–L4 | 1.141 (0.203) |
| T score hip | −0.92 (1.14) |
| T score L2–L4 | −0.29 (1.77) |
| Z score hip | −0.81 (1.04) |
| Z score L2–L4 | −0.31 (1.71) |
| Medication | |
| NSAID, current, n (%) | 49 (100) |
| DMARD, current, n (%) | 12 (24.5) |
| Corticosteroids, current, n (%) | 1 (2.0) |
| Bisphosphonates, current, n (%) | 3 (6.1) |
AS: ankylosing spondylitis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BASDAI: Bath AS Disease Activity Index; BASFI: Bath AS Functional Index; BASMI: Bath AS Metrology Index; IBD: inflammatory bowel disease; mSASSS: modified Stoke Ankylosing Spondylitis Spine Score; ThSpine: thoracic spine; BMD: bone mineral density; BMI: body mass index; VFx: vertebral fractures; NSAID: nonsteroidal antiinflammatory drug; DMARD: disease-modifying antirheumatic drug.